HBV vaccine efficacy and detection and genotyping of vaccineé asymptomatic breakthrough HBV infection in Egypt

作     者：Eman AE Abushady Magda MA Gameel John D Klena Salwa F Ahmed Kouka SE Abdel-wahab Sanya M Fahmy 

作者机构：Microbiology departmentFaculty of Medicine Nourthern Border UniversityArar 1321Saudi Arabia Microbiology departmentFaculty of MedicineAL-Azhar UniversityCairo R695-11651Egypt Molecular Epidemiology unitClinical Trials ProgramNAMRU-3Cairo 11157Egypt Pediatric departmentFaculty of MedicineAL-Azhar UniversityCairo R695-11651Egypt 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2011年第3卷第6期

页      面：147-156页

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：Biotechnology and Genetic Engineering National Strategy- Academy for Science Research and Biotechnology for their financial support to this project 

主　　题：HBV vaccine evaluation Egyptain children Adults Genotype E vaccine escape HBV 

摘      要：AIM:To evaluate the impact of mass vaccination against the hepatitis B virus (HBV) in Egypt,and to search for vaccinee asymptomatic breakthrough HBV infection and its ***:Seven hundred serum samples from vaccinated children and adults (aged 2-47 years) were used for quantitative and qualitative detection of HBsAb by *** hundred and sixty serum samples representing undetectable or low or high HBsAb were screened for markers of active HBV infection (HBsAg,HBcAb (IgG) and HBeAb by ELISA,plus HBsAg by AxSYM) and HBV-DNA genotyping by nested multiplex PCR and by DNA ***:It was found that 65% of children aged 2-4 years,and 20.5% aged 4-13 years,as well as 45% adults were good responders to HBV vaccination mounting protective level *** responders were 28%,59.5% and 34%,and non-responders were 7%,20% and 21% respectively,in the three studied *** of asymptomatic HBV infections were HBsAg detected by ELISA in 2.5% vs 11.39% by *** markers were HBcAb (IgG) in 1.38%,HBeAb in 0.83%,and HBV-DNA in 7.8%.All had HBV genotype E ***:It is concluded that HBV vaccine is efficient in controlling HBV infection among children and *** vaccine breakthrough infection was by HBV genotype E.A booster dose of vaccine is recommended,probably four years after initial vaccination.